Genocea Biosciences, Inc. – Trademark Portfolio
Entity Type: 03
Genocea Biosciences, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include INHIBIGENS. The owner is based in Cambridge, MA.
100 Acorn Park Drive
Cambridge, MA 02140
Showing of trademarks Trademarks
Trademark Classifications
Genocea Biosciences, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Genocea Biosciences, Inc. have?
Genocea Biosciences, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 4 cancelled.
What trademark classes does Genocea Biosciences, Inc. file in?
Genocea Biosciences, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Genocea Biosciences, Inc.'s most well-known trademarks?
Genocea Biosciences, Inc.'s registered trademark portfolio includes well-known marks such as INHIBIGENS. These are among 1 currently registered trademark in the portfolio.
What is Genocea Biosciences, Inc.'s trademark registration success rate?
Genocea Biosciences, Inc. has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.